PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (...
April 17 2018 - 1:01AM
REGULATED INFORMATION
GHENT, Belgium, 17 April 2018 - Ablynx
[Euronext Brussels and Nasdaq: ABLX] today announced, in
accordance with Article 14 of the Belgian Law of 2 May 2007
regarding the publication of major shareholdings in issuers whose
securities are admitted to trading on a regulated market (the
"Transparency Law"), that it received a notification of
shareholdings from BlackRock, Inc. on 11 and 13 April 2018.
BlackRock, Inc. (taking into account the
holdings of its subsidiary undertakings) notified Ablynx that it
has upward crossed the 3% threshold of voting rights attached to
shares for BlackRock, Inc. on 9 April 2018 and downward crossed
again on 12 April 2018.
BlackRock, Inc. now holds a total of 3,862,445
voting securities of Ablynx, representing 5.13% of the current
75,253,667 outstanding voting rights of Ablynx (versus 5.27%
notified previously on 10 April 2018).
The most recent notification contains the
following information:
- Reason for the notification: acquisition or disposal of
voting securities or voting rights
- Notification by: a parent undertaking or a controlling
person
- Persons subject to the notification requirement:
Name |
Address (for legal entities) |
BlackRock, Inc. |
55 East 52nd Street, New York, NY, 10055, U.S.A. |
BlackRock (Netherlands) B.V. |
Rembrandt Tower, 17th floor, Amstelplein, Amsterdam,
Netherlands |
BlackRock Advisors (UK) Limited |
12 Throgmorton Avenue, London, EC2N 2DL, U.K. |
BlackRock Advisors, LLC |
100 Bellevue Parkway, Wilmington, DE, 19809, U.S.A. |
BlackRock Asset Management Canada Limited |
161 Bay Street, Suite 2500, Toronto, Ontario, M5J 2S1, Canada |
BlackRock Asset Management Deutschland AG |
Max-Joseph-Straße 6, Munich, 80333, Germany |
BlackRock Asset Management North Asia Limited |
15/F, 16/F, 17/F Citibank Tower & 17/F ICBC Tower, 3 Garden
Road, Central, Hong Kong |
BlackRock Financial Management, Inc. |
55 East 52nd Street, New York, NY, 10055, U.S.A. |
BlackRock Fund Advisors |
400 Howard Street, San Francisco, CA, 94105, U.S.A. |
BlackRock Institutional Trust Company, National Association |
400 Howard Street, San Francisco, CA, 94105, U.S.A. |
BlackRock Investment Management (Australia) Limited |
Level 37, Chifley Tower, 2 Chifley Square, Sydney NSW 2000
Australia |
BlackRock Investment Management (UK) Limited |
12 Throgmorton Avenue, London, EC2N 2DL, U.K. |
BlackRock Investment Management, LLC |
1 University Square Drive, Princeton, NJ, 8540, U.S.A. |
BlackRock Japan Co., Ltd. |
1-8-3 Marunouchi Chiyoda-ku, Trust Tower Main, Tokyo, 100-8217,
Japan |
- Transaction date: 12 April 2018
- Threshold that is crossed: 3%
- Denominator: 75,253,667
- Details of the notification:
Name of select subsidiaries of BlackRock |
% of voting rights |
% of voting rights held through financial instruments* |
Total of both |
BlackRock (Netherlands) B.V. |
0.01% |
|
0.01% |
BlackRock Advisors (UK) Limited |
1.27% |
0.04% 1 / 0.15% 3 |
1.46% |
BlackRock Advisors, LLC |
|
0.27% 2 |
0.27% |
BlackRock Asset Management Canada Limited |
0.01% |
|
0.01% |
BlackRock Asset Management Deutschland AG |
0.26% |
|
0.26% |
BlackRock Asset Management North Asia Limited |
|
0.00% 3 |
0.00% |
BlackRock Fund Advisors |
0.77% |
0.07% 1 |
0.84% |
BlackRock Institutional Trust Company, National Association |
0.45% |
0.07% 1 / 0.11% 2 |
0.63% |
BlackRock Investment Management (Australia) Limited |
0.00% |
|
0.00% |
BlackRock Investment Management (UK) Limited |
0.05% |
0.01% 3 |
0.06% |
BlackRock Investment Management, LLC |
0.00% |
0.80% 2 / 0.00% 3 |
0.80% |
BlackRock Japan Co., Ltd |
0.07% |
0.06% 3 |
0.13% |
BlackRock Financial Management, Inc. |
|
0.67% 2 |
0.67% |
TOTAL |
2.88%(previously 2.84%) |
2.25%(previously 2.43%) |
5.13% (previously 5.27%) |
* Type of financial instrument: 1'Securities
lent' and 2'Contract for Difference' and 3'Depository Receipt'
- Chain of controlled undertakings through which the holding
is effectively being held: Please see the full chain of control
in the Transparency Notification.
- Additional information: The disclosure obligation arose
due to voting rights attached to shares for BlackRock, Inc. going
above and below 3%.
A full version of the transparency notification
is available on Ablynx website, under the section Investors.
The Articles of the Association of Ablynx NV
provide for shareholders notification threshold of 3%, 5% or a
multiple of 5% of the total number of existing voting rights.
About Ablynx
Ablynx is a biopharmaceutical company engaged in
the development of Nanobodies, proprietary therapeutic proteins
based on single-domain antibody fragments, which combine the
advantages of conventional antibody drugs with some of the features
of small-molecule drugs. Ablynx is dedicated to creating new
medicines which will make a real difference to society. Today, the
Company has more than 45 proprietary and partnered programmes in
development in various therapeutic areas including inflammation,
haematology, immuno-oncology, oncology and respiratory disease. The
Company has collaborations with multiple pharmaceutical companies
including AbbVie; Boehringer Ingelheim; Eddingpharm; Merck &
Co., Inc., Kenilworth, New Jersey, USA; Merck KGaA; Novo Nordisk;
Sanofi and Taisho Pharmaceuticals. The Company is headquartered in
Ghent, Belgium. More information can be found on
www.ablynx.com.
On 29 January 2018, Sanofi made an offer to
acquire all of Ablynx's outstanding ordinary shares (including
shares represented by American Depository Shares (ADSs), warrants
and convertible bonds) at a price of €45 per share, which
represents an aggregate equity value of approximately €3.9 billion.
The proposed transaction was unanimously approved by both the
Sanofi and Ablynx Board of Directors. The initial tender offer
commenced on 4 April 2018 and will expire on 4 May 2018, subject to
extension. Sanofi has published an offer document in which it set
out the full details of its tender offer, and the Board of
Directors of Ablynx published a response memorandum ('memorie van
antwoord'), in which it set out its position on the tender
offer.
For more information, please
contactAblynx:Dr Edwin MosesCEOt: +32 (0)9
262 00 07m: +32 (0)473 39 50 68e: edwin.moses@ablynx.com
Lies VannesteDirector Investor Relationst: +32 (0)9
262 01 37m: +32 (0)498 05 35 79 e:
lies.vanneste@ablynx.com
Follow us on Twitter @AblynxABLX
Ablynx media relations:Consilium Strategic
CommunicationsMary-Jane Elliott, Philippa Gardner, Sukaina
Virjit: +44 (0)20 3709 5700e:
ablynx@consilium-comms.com
Joele Frank, Wilkinson Brimmer KatcherDan
Katcher or Joseph Salat: +1 212-355-4449
- pdf version of the press release.pdf